[Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
OBJECTIVE
To clarify the association of EGFR expression with angiogenesis and chemoresistance in ovarian cancer.


METHODS
Immunohistochemical PV-6000 staining was used to detect the expression of EGFR, LRP protein and MVD in 102 ovarian tumor specimens.


RESULTS
EGFR, LRP positive rates and MVD in borderline and malignant ovarian specimens were significantly higher than those in the normal and benign ones (P < 0.01). EGFR positive expression rate in stage III-IV carcinoma tissues, poor differentiation and with ascites was higher than that in stage I-II carcinomas of well differentiation and without ascites (P < 0.05). MVD was related to histological grade, residual tumor and ascites, LRP positive expression had no correlation with the clinicopathologic parameters (P > 0.05). The effective rate of chemotherapy in patients with EGFR and LRP-positive expression were 57.1% and 53.7%, respectively, significantly lower than that in cases with EGFR and LRP-negative expression (85.0% and 90.9%, P < 0.05). In the 64 cases with complete data, the three-year survival rate was 53.0%. The survival time was shorter in the cases with EGFR and LRP-positive expression, poor differentiation, ascites and chemoresistance (P < 0.01), and only LRP-positive expression and chemotherapeutic effect were independently related to survival time (P < 0.05). There was a correlation between EGFR and MVD (r = 0.548, P < 0.01), EGFR and LRP positive expression (P = 0.020).


CONCLUSIONS
The expression of EGFR in ovarian cancer is related to angiogenesis and chemoresistance. EGFR and LRP-positive expression are related to chemoresistance, and detection of the two proteins may be helpful in guiding chemotherapy choice for ovarian cancer. LRP-positive expression and chemotherapeutic effect may be independent prognostic factors.
Chen
Ai-ping
AP
Department of Gynecology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China. chenaiping516@163.com
Zhang
Jing
J
Liu
Hui
H
Zhao
Shu-ping
SP
Dai
Shu-zhen
SZ
Sun
Xian-lu
XL
D018952:Antigens, CD34 / Q000378:metabolism; D001201:Ascites / Q000473:pathology; D018282:Cystadenocarcinoma, Mucinous / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018291:Cystadenoma, Mucinous / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018293:Cystadenoma, Serous / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015996:Survival Rate; D020394:Vault Ribonucleoprotein Particles / Q000378:metabolism*; D000099187:Major Vault Protein
D018952:Antigens, CD34; D066246:ErbB Receptors; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein